Logo image of VNDA

VANDA PHARMACEUTICALS INC (VNDA) Stock Fundamental Analysis

NASDAQ:VNDA - Nasdaq - US9216591084 - Common Stock - Currency: USD

4.22  +0.01 (+0.24%)

After market: 4.22 0 (0%)

Fundamental Rating

3

Taking everything into account, VNDA scores 3 out of 10 in our fundamental rating. VNDA was compared to 551 industry peers in the Biotechnology industry. While VNDA is still in line with the averages on profitability rating, there are concerns on its financial health. VNDA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

VNDA had negative earnings in the past year.
VNDA had a negative operating cash flow in the past year.
VNDA had positive earnings in 4 of the past 5 years.
Of the past 5 years VNDA 4 years had a positive operating cash flow.
VNDA Yearly Net Income VS EBIT VS OCF VS FCFVNDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

The Return On Assets of VNDA (-10.71%) is better than 83.85% of its industry peers.
VNDA has a better Return On Equity (-13.76%) than 87.84% of its industry peers.
Industry RankSector Rank
ROA -10.71%
ROE -13.76%
ROIC N/A
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
VNDA Yearly ROA, ROE, ROICVNDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

With an excellent Gross Margin value of 94.40%, VNDA belongs to the best of the industry, outperforming 94.74% of the companies in the same industry.
VNDA's Gross Margin has been stable in the last couple of years.
VNDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
VNDA Yearly Profit, Operating, Gross MarginsVNDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VNDA has been increased compared to 1 year ago.
The number of shares outstanding for VNDA has been increased compared to 5 years ago.
VNDA has a worse debt/assets ratio than last year.
VNDA Yearly Shares OutstandingVNDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
VNDA Yearly Total Debt VS Total AssetsVNDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of 0.88, we must say that VNDA is in the distress zone and has some risk of bankruptcy.
VNDA has a Altman-Z score of 0.88. This is in the better half of the industry: VNDA outperforms 64.25% of its industry peers.
VNDA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.01, VNDA perfoms like the industry average, outperforming 43.19% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 0.88
ROIC/WACCN/A
WACC10.85%
VNDA Yearly LT Debt VS Equity VS FCFVNDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 3.25 indicates that VNDA has no problem at all paying its short term obligations.
With a Current ratio value of 3.25, VNDA is not doing good in the industry: 62.07% of the companies in the same industry are doing better.
VNDA has a Quick Ratio of 3.23. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
VNDA has a worse Quick ratio (3.23) than 60.25% of its industry peers.
Industry RankSector Rank
Current Ratio 3.25
Quick Ratio 3.23
VNDA Yearly Current Assets VS Current LiabilitesVNDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

VNDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -494.74%.
The Revenue has grown by 11.78% in the past year. This is quite good.
VNDA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.64% yearly.
EPS 1Y (TTM)-494.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
Revenue 1Y (TTM)11.78%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%4.19%

3.2 Future

The Earnings Per Share is expected to grow by 23.95% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 1.13% on average over the next years.
EPS Next Y-376%
EPS Next 2Y-11.02%
EPS Next 3Y23.95%
EPS Next 5YN/A
Revenue Next Year14.18%
Revenue Next 2Y26.33%
Revenue Next 3Y22.5%
Revenue Next 5Y1.13%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VNDA Yearly Revenue VS EstimatesVNDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
VNDA Yearly EPS VS EstimatesVNDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VNDA. In the last year negative earnings were reported.
Also next year VNDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VNDA Price Earnings VS Forward Price EarningsVNDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VNDA Per share dataVNDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

VNDA's earnings are expected to grow with 23.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.02%
EPS Next 3Y23.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VNDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VANDA PHARMACEUTICALS INC

NASDAQ:VNDA (8/6/2025, 4:01:46 PM)

After market: 4.22 0 (0%)

4.22

+0.01 (+0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)11-04 2025-11-04
Inst Owners77.72%
Inst Owner Change-0.36%
Ins Owners6.63%
Ins Owner Change23.2%
Market Cap248.68M
Analysts80
Price Target12.92 (206.16%)
Short Float %8.4%
Short Ratio10.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.3%
Min EPS beat(2)-26.44%
Max EPS beat(2)17.84%
EPS beat(4)3
Avg EPS beat(4)15.96%
Min EPS beat(4)-26.44%
Max EPS beat(4)45.98%
EPS beat(8)6
Avg EPS beat(8)5.71%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.57%
Min Revenue beat(2)-5.56%
Max Revenue beat(2)8.7%
Revenue beat(4)1
Avg Revenue beat(4)-0.51%
Min Revenue beat(4)-5.56%
Max Revenue beat(4)8.7%
Revenue beat(8)3
Avg Revenue beat(8)0.35%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)17.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-64.61%
EPS NY rev (1m)0%
EPS NY rev (3m)-33.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.3%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.22
P/FCF N/A
P/OCF N/A
P/B 0.51
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS3.45
BVpS8.25
TBVpS6.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.71%
ROE -13.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.4%
FCFM N/A
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.98%
Cap/Sales 0.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.25
Quick Ratio 3.23
Altman-Z 0.88
F-Score3
WACC10.85%
ROIC/WACCN/A
Cap/Depr(3y)14.89%
Cap/Depr(5y)25.49%
Cap/Sales(3y)0.24%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-494.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
EPS Next Y-376%
EPS Next 2Y-11.02%
EPS Next 3Y23.95%
EPS Next 5YN/A
Revenue 1Y (TTM)11.78%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%4.19%
Revenue Next Year14.18%
Revenue Next 2Y26.33%
Revenue Next 3Y22.5%
Revenue Next 5Y1.13%
EBIT growth 1Y-210.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-263.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-258.43%
OCF growth 3YN/A
OCF growth 5YN/A